Efficacy and Safety of FLT3 Inhibitors in FLT3-Mutated Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (SOHO 2026) - Sep 1, 2026 - Abstract #AML-1748; Location: LEVEL 3, HALL B3; "FLT3 inhibitors significantly improve OS, remission rates, and relapse-free survival in FLT3-mutated AML across all disease settings. Gilteritinib and quizartinib demonstrate superior FLT3 selectivity and efficacy to sorafenib in the ND and R/R settings. MRD status emerges as a critical modifier of post-HCT maintenance benefit."
Retrospective data • Review • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3
|
|
Basil Joy MBBS 1; Alvin Antony MBBS 2; Ajina Joy MBBS 1; Abraham Joy MBBS 3
|